Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

References

• KammCPUitdehaagBMPolmanCHMultiple sclerosis: current knowledge and future outlookEur Neurol20147213214125095894
   PubMed Web of Science ®Google Scholar
• KasperLHRederATImmunomodulatory activity of interferon-betaAnn Clin Transl Neurol2014162263125356432
   PubMed Web of Science ®Google Scholar
• No authors listedInterferon b-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• PatyDWLiDKInterferon beta lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology1993436626678469319
   PubMed Web of Science ®Google Scholar
• RudickRAGoodkinDEJacobsLDImpact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Neurology1997493583639270562
   PubMed Web of Science ®Google Scholar
• SimonJHJacobsLDCampionMMagnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupAnn Neurol19984379879450771
   PubMed Web of Science ®Google Scholar
• No authors listedRandomised double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• AnnibaliVMechelliRRomanoSIFN-β and multiple sclerosis: from etiology to therapy and backCytokine Growth Factor Rev10312014 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDSFrancisGRandomized, comparative study of interferon b-1a treatment regimens in MS. The EVIDENCE TrialNeurology2002591496150612451188
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon-beta-1a therapy initiated during a first demyelinating event in multiple sclerosisN Engl J Med200034389890411006365
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMBarkhofFEffect of early interferon treatment on conversion to definite multiple sclerosis: a randomized studyLancet20013571576158211377645
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006671242124916914693
   PubMed Web of Science ®Google Scholar
• No authors listedPlacebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive MS. European Study Group on Interferon Beta-1b in Secondary Progressive MSLancet1998352149114979820296
   PubMed Web of Science ®Google Scholar
• PanitchHMillerAPatyDWeinshenker B; North American Study Group on Interferon beta-1b in Secondary ProgressiveMSInterferon beta-1b in secondary progressive MS: results from a 3-year controlled studyNeurology2004631788179515557491
   PubMed Web of Science ®Google Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon- beta-1 in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical resultsNeurology2001561496150411402106
   PubMed Web of Science ®Google Scholar
• LiDKZhaoGJPatyDWUniversity of British Columbia MS/MRI Analysis Research Group, The SPECTRIMS Study GroupRandomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI resultsNeurology2001561505151311402107
   PubMed Web of Science ®Google Scholar
• CohenJACutterGRFischerJSBenefit of interferon beta-1a on MSFC progression in secondary progressive MSNeurology20025967968712221157
   PubMed Web of Science ®Google Scholar
• FrisulloGCalabreseMTortorellaCThyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter studyMult Scler2014201265126824515732
   PubMed Web of Science ®Google Scholar
• HuntDKavanaghDDrummondIThrombotic microangiopathy associated with interferon betaN Engl J Med20143701270127124670186
   PubMed Web of Science ®Google Scholar
• GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler20121893294622249762
   PubMed Web of Science ®Google Scholar
• BailonPWonCYPEG-modified biopharmaceuticalsExpert Opin Drug Deliv2009611619236204
   PubMed Web of Science ®Google Scholar
• PisalDSKosloskiMPBalu-IyerSVDelivery of therapeutic proteinsJ Pharm Sci2010992557257520049941
   PubMed Web of Science ®Google Scholar
• WangXIshidaTKiwadaHAnti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomesJ Control Release200711923624417399838
   PubMed Web of Science ®Google Scholar
• RaoHYLiJZhangLFEffect of PEGylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysisZhonghua Yi Xue Za Zhi20088896100 Chinese18353212
   PubMedGoogle Scholar
• BasuAYangKWangMStructure-function engineering of interferon beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylationBioconjug Chem20061761863016704199
   PubMed Web of Science ®Google Scholar
• MagerDENeuteboomBJuskoWJPharmacokinetics and pharmacodynamics of pegylated IFN-beta 1a following subcutaneous administration in monkeysPharm Res200522586115771230
   PubMed Web of Science ®Google Scholar
• ReussRPEGylated interferon beta-1a in the treatment of multiple sclerosis – an updateBiologics2013713113823807836
   PubMedGoogle Scholar
• HuXMillerLRichmanSA novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biologyJ Clin Pharmacol20125279880821680782
   PubMed Web of Science ®Google Scholar
• HuXSeddighzadehAStecherSPharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal functionJ Clin Pharmacol20155517918825187030
   PubMed Web of Science ®Google Scholar
• CalabresiPAKieseierBCArnoldDLADVANCE Study InvestigatorsPegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, Phase 3, double-blind studyLancet Neurol20141365766524794721
   PubMed Web of Science ®Google Scholar
• KieseierBCArnoldDLBalcerLJPeginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEMult Scler11282014 Epub ahead of print
   Google Scholar
• ArnoldDLCalabresiPAKieseierBCEffect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosisBMC Neurol201414105825551571
   PubMed Web of Science ®Google Scholar
• SeddighzadehAHungSSelmajKSingle-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN studyExpert Opin Drug Deliv2014111713172025073663
   PubMed Web of Science ®Google Scholar
• BendeleASeelyJRicheyCSennelloGShoppGShort communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteinsToxicol Sci1998421521579579027
   PubMed Web of Science ®Google Scholar
• YoungMAMalavalliAWinslowNVandegriffKDWinslowRMToxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeysTransl Res200714933334217543852
   PubMed Web of Science ®Google Scholar
• InusahSSormaniMPCofieldSSAssessing changes in relapse rates in multiple sclerosisMult Scler2010161414142120810517
   PubMed Web of Science ®Google Scholar
• SormaniMPThe Will Rogers phenomenon: the effect of different diagnostic criteriaJ Neurol Sci2009287S46S4920106348
   PubMed Web of Science ®Google Scholar